Market Overview:
The global integrin beta 1 market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of genetic disorders, rising demand for better treatment options, and growing awareness about integrin beta 1-based therapies. By type, the AXT-108 segment is expected to account for the largest share of the global integrin beta 1 market in 2018. This segment is also projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030.
Product Definition:
An integrin is a type of receptor protein that interacts with the extracellular matrix, which is a network of proteins and carbohydrates that surrounds cells. There are many different types of integrins, but one particular type, beta 1 integrin, has been extensively studied because it plays an important role in cell adhesion and migration.
AXT-108:
Integrin beta 1 (ITGB1) is a protein that belongs to the family of integrin receptors. It is also known as platelet-derived growth factor receptor or PDGFR). The primary function of this receptor is to regulate cell proliferation and differentiation. This leads to the growth in revenue for AXT-108, which has been observed by many companies over recent years, with no signifigant side effects in man or animal trials thus far.
C-16Y:
C-16Y is a nonapeptide, naturally occurring amino acid found in humans and other animals. It is used as an analytical tool for the determination of integrin beta 1 (ITGB1) based on its binding properties with the help of ELISA technique. The C-16Y test has high sensitivity, linearity, and range compared to other commercial assays available in the market which makes it one of the most preferred tests for ITGB1 analysis.
Application Insights:
Genetic disorders segment held the largest share of genetic disorders application in 2015. This is due to the rising prevalence of genetic diseases such as hemoglobinopathy, cystic fibrosis, and others. In addition, a rise in research activities for the development of new therapeutics for these diseases is also responsible for this segment¢â‚¬â„¢s largest share.
Integrin beta 1 inhibitors are under extensive research & development phase for their use in various disease states such as cancer, diabetes mellitus type 2 and obesity which accounts for a significant market revenue share by itself. The increasing R&D investments by various companies on a priority basis towards clinical trials are expected to drive this drug candidate pipeline over the forecast period thereby contributing significantly to market growth during future years.
Regional Analysis:
North America dominated the global integrin beta 1 market in terms of revenue with a share of over 40.0% in 2017. This is due to the presence of key players such as Pfizer, Inc.; Johnson & Johnson Services, Inc.; and Merck KGaA that are engaged in extensive R&D activities for development of novel drugs targeting different diseases. Moreover, increasing prevalence of chronic disorders coupled with rising adoption rate for advanced treatment options is expected to drive regional growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative CAGR over the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure.
Growth Factors:
- Increasing incidence of chronic diseases such as cancer, cardiovascular diseases, and diabetes is expected to drive the demand for integrin beta 1 inhibitors over the forecast period.
- Growing geriatric population is also anticipated to boost the market growth owing to increasing prevalence of age-related disorders such as macular degeneration and arthritis.
- Rising awareness about benefits offered by integrin beta 1 inhibitors in treatment of various chronic diseases is projected to propel the demand for these drugs in coming years.
- Technological advancements in drug delivery systems are likely to provide lucrative opportunities for market players over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Integrin Beta 1 Market Research Report
By Type
AXT-108, C-16Y, CLT-28643, SAL-021, Others
By Application
Genetic Disorders, Dermatology, Cardiovascular, Others
By Companies
Avipero Ltd, Clanotech AB, Morphic Therapeutic Inc, Strykagen Corp, Valeant Pharmaceuticals International Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Integrin Beta 1 Market Report Segments:
The global Integrin Beta 1 market is segmented on the basis of:
Types
AXT-108, C-16Y, CLT-28643, SAL-021, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Genetic Disorders, Dermatology, Cardiovascular, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Avipero Ltd
- Clanotech AB
- Morphic Therapeutic Inc
- Strykagen Corp
- Valeant Pharmaceuticals International Inc
Highlights of The Integrin Beta 1 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AXT-108
- C-16Y
- CLT-28643
- SAL-021
- Others
- By Application:
- Genetic Disorders
- Dermatology
- Cardiovascular
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Integrin Beta 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Integrin beta 1 is a protein that helps cells attach to other cells and tissues. It also helps the body move materials around inside and outside of cells.
Some of the key players operating in the integrin beta 1 market are Avipero Ltd, Clanotech AB, Morphic Therapeutic Inc, Strykagen Corp, Valeant Pharmaceuticals International Inc.
The integrin beta 1 market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Integrin Beta 1 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Integrin Beta 1 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Integrin Beta 1 Market - Supply Chain
4.5. Global Integrin Beta 1 Market Forecast
4.5.1. Integrin Beta 1 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Integrin Beta 1 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Integrin Beta 1 Market Absolute $ Opportunity
5. Global Integrin Beta 1 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Integrin Beta 1 Market Size and Volume Forecast by Type
5.3.1. AXT-108
5.3.2. C-16Y
5.3.3. CLT-28643
5.3.4. SAL-021
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Integrin Beta 1 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Integrin Beta 1 Market Size and Volume Forecast by Application
6.3.1. Genetic Disorders
6.3.2. Dermatology
6.3.3. Cardiovascular
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Integrin Beta 1 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Integrin Beta 1 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Integrin Beta 1 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Integrin Beta 1 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Integrin Beta 1 Demand Share Forecast, 2019-2026
9. North America Integrin Beta 1 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Integrin Beta 1 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Integrin Beta 1 Market Size and Volume Forecast by Application
9.4.1. Genetic Disorders
9.4.2. Dermatology
9.4.3. Cardiovascular
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Integrin Beta 1 Market Size and Volume Forecast by Type
9.7.1. AXT-108
9.7.2. C-16Y
9.7.3. CLT-28643
9.7.4. SAL-021
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Integrin Beta 1 Demand Share Forecast, 2019-2026
10. Latin America Integrin Beta 1 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Integrin Beta 1 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Integrin Beta 1 Market Size and Volume Forecast by Application
10.4.1. Genetic Disorders
10.4.2. Dermatology
10.4.3. Cardiovascular
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Integrin Beta 1 Market Size and Volume Forecast by Type
10.7.1. AXT-108
10.7.2. C-16Y
10.7.3. CLT-28643
10.7.4. SAL-021
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Integrin Beta 1 Demand Share Forecast, 2019-2026
11. Europe Integrin Beta 1 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Integrin Beta 1 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Integrin Beta 1 Market Size and Volume Forecast by Application
11.4.1. Genetic Disorders
11.4.2. Dermatology
11.4.3. Cardiovascular
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Integrin Beta 1 Market Size and Volume Forecast by Type
11.7.1. AXT-108
11.7.2. C-16Y
11.7.3. CLT-28643
11.7.4. SAL-021
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projectons by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Integrin Beta 1 Demand Share, 2019-2026
12. Asia Pacific Integrin Beta 1 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Integrin Beta 1 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Integrin Beta 1 Market Size and Volume Forecast by Application
12.4.1. Genetic Disorders
12.4.2. Dermatology
12.4.3. Cardiovascular
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Integrin Beta 1 Market Size and Volume Forecast by Type
12.7.1. AXT-108
12.7.2. C-16Y
12.7.3. CLT-28643
12.7.4. SAL-021
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Integrin Beta 1 Demand Share, 2019-2026
13. Middle East & Africa Integrin Beta 1 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Integrin Beta 1 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Integrin Beta 1 Market Size and Volume Forecast by Application
13.4.1. Genetic Disorders
13.4.2. Dermatology
13.4.3. Cardiovascular
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Integrin Beta 1 Market Size and Volume Forecast by Type
13.7.1. AXT-108
13.7.2. C-16Y
13.7.3. CLT-28643
13.7.4. SAL-021
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Integrin Beta 1 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Integrin Beta 1 Market: Market Share Analysis
14.2. Integrin Beta 1 Distributors and Customers
14.3. Integrin Beta 1 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Avipero Ltd
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Clanotech AB
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Morphic Therapeutic Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Strykagen Corp
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Valeant Pharmaceuticals International Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
